|
||
Date of Report (Date of earliest event reported)
|
|
||
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
||
(Address of principal executive offices and zip code)
|
(
|
||
(Registrant’s telephone number, including area code)
|
N/A
|
||
(Former name or former address, if changed since last report)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
Item 9.01
|
Financial Statements and Exhibits.
|
99.1 |
Nu Skin Enterprises’ press release dated November 5, 2019, regarding financial results for the three- and nine-month periods ended September 30, 2019.
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
NU SKIN ENTERPRISES, INC.
|
||
(Registrant)
|
||
/s/ Mark H. Lawrence
|
||
Mark H. Lawrence
|
||
Chief Financial Officer
|
Revenue:
|
$589.9 million; (13%)
• (2%) fx impact or ($12 M)
|
||
Earnings Per Share
(EPS):
|
$0.79; (16%)
|
||
Sales Leaders:
|
61,090; (16%)
|
||
Customers:
|
1,206,697;+4%
|
Revenue:
|
$589.9 million compared to $675.3 million
• (2%) fx impact or ($12 M)
|
||
Gross Margin:
|
76.2% compared to 76.7%
• Nu Skin business was 78.6% compared to 78.7%
|
||
Selling Expenses:
|
39.3% of revenue compared to 40.2%
• Nu Skin business was 41.5% compared to 41.8%
|
||
G&A Expenses:
|
25.1% of revenue compared to 24.5%
|
||
Operating Margin:
|
11.8% compared to 11.9%
|
||
Other Income /
(Expense):
|
($5.0) million compared to ($7.0) million
|
||
Income Tax Rate:
|
32.1% compared to 27.9%
|
||
EPS:
|
$0.79 compared to $0.94
|
Dividend Payments:
|
$20.6 million
|
||
Stock Repurchases:
|
Nil
|
Q4 2019 Revenue:
|
• Approximately (2%) fx impact
|
||
Q4 2019 EPS:
|
$0.68 to $0.75
|
||
2019 Revenue:
|
• Approximately (4%) fx impact
|
||
2019 EPS
|
$3.07 to $3.14
|
• |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
• |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or
enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of
fines, or any other adverse actions or events;
|
• |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and
selling activities on a sustained basis;
|
• |
uncertainty regarding the continued impact of the 100-day review and negative media and consumer sentiment in Mainland China on our business operations and
results;
|
• |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
• |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
• |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and
increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
• |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue
selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
|
• |
unpredictable economic conditions and events globally, including trade policies and tariffs;
|
• |
uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company’s future
tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax
laws in the company’s various markets; and
|
• |
continued competitive pressures in the company’s markets.
|
Three Months Ended
September 30,
|
Constant-
Currency
|
|||||||||||||||
2019
|
2018
|
Change
|
Change
|
|||||||||||||
Nu Skin
|
||||||||||||||||
Mainland China
|
$
|
173,974
|
$
|
226,645
|
(23
|
)%
|
(21
|
)%
|
||||||||
Americas/Pacific
|
83,635
|
93,580
|
(11
|
)%
|
(7
|
)%
|
||||||||||
South Korea
|
79,435
|
89,963
|
(12
|
)%
|
(6
|
)%
|
||||||||||
Southeast Asia
|
78,963
|
86,307
|
(9
|
)%
|
(10
|
)%
|
||||||||||
Japan
|
67,197
|
63,649
|
6
|
%
|
2
|
%
|
||||||||||
Hong Kong/Taiwan
|
40,449
|
44,949
|
(10
|
)%
|
(9
|
)%
|
||||||||||
EMEA
|
35,742
|
42,819
|
(17
|
)%
|
(13
|
)%
|
||||||||||
Other
|
(62
|
)
|
1,378
|
(104
|
)%
|
(104
|
)%
|
|||||||||
Total Nu Skin
|
559,333
|
649,290
|
(14
|
)%
|
(12
|
)%
|
||||||||||
Manufacturing
|
30,601
|
26,022
|
18
|
%
|
18
|
%
|
||||||||||
Grow Tech
|
—
|
—
|
—
|
—
|
||||||||||||
Total
|
$
|
589,934
|
$
|
675,312
|
(13
|
)%
|
(11
|
)%
|
Nine Months Ended
September 30,
|
Constant-
Currency
|
|||||||||||||||
2019
|
2018
|
Change
|
Change
|
|||||||||||||
Nu Skin
|
||||||||||||||||
Mainland China
|
$
|
567,795
|
$
|
669,432
|
(15
|
)%
|
(11
|
)%
|
||||||||
Americas/Pacific
|
262,932
|
289,859
|
(9
|
)%
|
(3
|
)%
|
||||||||||
South Korea
|
248,020
|
270,517
|
(8
|
)%
|
(2
|
)%
|
||||||||||
Southeast Asia
|
226,853
|
236,390
|
(4
|
)%
|
(3
|
)%
|
||||||||||
Japan
|
194,557
|
190,986
|
2
|
%
|
1
|
%
|
||||||||||
Hong Kong/Taiwan
|
124,719
|
138,147
|
(10
|
)%
|
(8
|
)%
|
||||||||||
EMEA
|
120,960
|
131,810
|
(8
|
)%
|
(2
|
)%
|
||||||||||
Other
|
(239
|
)
|
2,643
|
(109
|
)%
|
(109
|
)%
|
|||||||||
Total Nu Skin
|
1,745,597
|
1,929,784
|
(10
|
)%
|
(6
|
)%
|
||||||||||
Manufacturing
|
91,430
|
65,937
|
39
|
%
|
39
|
%
|
||||||||||
Grow Tech
|
30
|
—
|
—
|
—
|
||||||||||||
Total
|
$
|
1,837,057
|
$
|
1,995,721
|
(8
|
)%
|
(4
|
)%
|
As of
September 30, 2019
|
As of
September 30, 2018
|
% Increase (Decrease)
|
||||||||||||||||||||||
Customers
|
Sales
Leaders
|
Customers
|
Sales
Leaders
|
Customers
|
Sales
Leaders
|
|||||||||||||||||||
Mainland China
|
317,257
|
23,776
|
210,212
|
33,335
|
51
|
%
|
(29
|
)%
|
||||||||||||||||
Americas/Pacific
|
229,013
|
7,760
|
276,923
|
8,475
|
(17
|
)%
|
(8
|
)%
|
||||||||||||||||
South Korea
|
169,589
|
7,363
|
180,254
|
7,700
|
(6
|
)%
|
(4
|
)%
|
||||||||||||||||
Southeast Asia
|
145,845
|
7,936
|
146,586
|
8,668
|
(1
|
)%
|
(8
|
)%
|
||||||||||||||||
Japan
|
128,373
|
5,964
|
130,831
|
6,182
|
(2
|
)%
|
(4
|
)%
|
||||||||||||||||
Hong Kong/Taiwan
|
68,862
|
4,231
|
75,985
|
4,402
|
(9
|
)%
|
(4
|
)%
|
||||||||||||||||
EMEA
|
147,758
|
4,060
|
144,977
|
4,320
|
2
|
%
|
(6
|
)%
|
||||||||||||||||
Total
|
1,206,697
|
61,090
|
1,165,768
|
73,082
|
4
|
%
|
(16
|
)%
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2019
|
2018
|
2019
|
2018
|
|||||||||||||
Revenue
|
$
|
589,934
|
$
|
675,312
|
$
|
1,837,057
|
$
|
1,995,721
|
||||||||
Cost of sales
|
140,162
|
157,457
|
440,854
|
472,287
|
||||||||||||
Gross profit
|
449,772
|
517,855
|
1,396,203
|
1,523,434
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Selling expenses
|
231,937
|
271,509
|
727,473
|
801,968
|
||||||||||||
General and administrative expenses
|
147,943
|
165,671
|
455,983
|
499,037
|
||||||||||||
Total operating expenses
|
379,880
|
437,180
|
1,183,456
|
1,301,005
|
||||||||||||
Operating income
|
69,892
|
80,675
|
212,747
|
222,429
|
||||||||||||
Other income (expense), net
|
(4,979
|
)
|
(6,982
|
)
|
(11,153
|
)
|
(16,940
|
)
|
||||||||
Income before provision for income taxes
|
64,913
|
73,693
|
201,594
|
205,489
|
||||||||||||
Provision for income taxes
|
20,823
|
20,547
|
68,153
|
65,843
|
||||||||||||
Net income
|
$
|
44,090
|
$
|
53,146
|
$
|
133,441
|
$
|
139,646
|
||||||||
Net income per share:
|
||||||||||||||||
Basic
|
$
|
0.79
|
$
|
0.96
|
$
|
2.40
|
$
|
2.54
|
||||||||
Diluted
|
$
|
0.79
|
$
|
0.94
|
$
|
2.39
|
$
|
2.47
|
||||||||
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
Basic
|
55,548
|
55,603
|
55,507
|
55,075
|
||||||||||||
Diluted
|
55,788
|
56,704
|
55,950
|
56,539
|
September 30,
2019
|
December 31,
2018
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
320,034
|
$
|
386,911
|
||||
Current investments
|
7,458
|
11,346
|
||||||
Accounts receivable
|
56,342
|
53,282
|
||||||
Inventories, net
|
282,997
|
295,821
|
||||||
Prepaid expenses and other
|
72,298
|
51,877
|
||||||
Total current assets
|
739,129
|
799,237
|
||||||
Property and equipment, net
|
447,653
|
464,535
|
||||||
Right-of-use assets
|
115,557
|
—
|
||||||
Goodwill
|
196,573
|
196,573
|
||||||
Other intangible assets, net
|
83,172
|
89,989
|
||||||
Other assets
|
154,821
|
144,112
|
||||||
Total assets
|
$
|
1,736,905
|
$
|
1,694,446
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
39,404
|
$
|
47,617
|
||||
Accrued expenses
|
304,003
|
322,583
|
||||||
Current portion of long-term debt
|
25,000
|
69,455
|
||||||
Total current liabilities
|
368,407
|
439,655
|
||||||
Operating lease liabilities
|
80,953
|
—
|
||||||
Long-term debt
|
341,724
|
361,008
|
||||||
Other liabilities
|
100,021
|
111,916
|
||||||
Total liabilities
|
891,105
|
912,579
|
||||||
Stockholders’ equity:
|
||||||||
Class A common stock
|
91
|
91
|
||||||
Additional paid-in capital
|
557,283
|
552,564
|
||||||
Treasury stock, at cost
|
(1,324,826
|
)
|
(1,326,605
|
)
|
||||
Accumulated other comprehensive loss
|
(94,961
|
)
|
(79,934
|
)
|
||||
Retained earnings
|
1,708,213
|
1,635,751
|
||||||
Total stockholders’ equity
|
845,800
|
781,867
|
||||||
Total liabilities and stockholders’ equity
|
$
|
1,736,905
|
$
|
1,694,446
|